JP7212144B2 - 非細胞性根管充填材および非細胞性歯組織再生促進キット - Google Patents
非細胞性根管充填材および非細胞性歯組織再生促進キット Download PDFInfo
- Publication number
- JP7212144B2 JP7212144B2 JP2021509662A JP2021509662A JP7212144B2 JP 7212144 B2 JP7212144 B2 JP 7212144B2 JP 2021509662 A JP2021509662 A JP 2021509662A JP 2021509662 A JP2021509662 A JP 2021509662A JP 7212144 B2 JP7212144 B2 JP 7212144B2
- Authority
- JP
- Japan
- Prior art keywords
- acellular
- root canal
- regeneration
- kit
- filling material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002631 root canal filling material Substances 0.000 title claims description 51
- 230000001737 promoting effect Effects 0.000 title claims description 47
- 230000017423 tissue regeneration Effects 0.000 title claims description 18
- 238000011069 regeneration method Methods 0.000 claims description 84
- 230000008929 regeneration Effects 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 60
- 210000001519 tissue Anatomy 0.000 claims description 56
- 108090000631 Trypsin Proteins 0.000 claims description 34
- 102000004142 Trypsin Human genes 0.000 claims description 34
- 239000012588 trypsin Substances 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 15
- 239000005482 chemotactic factor Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000003472 neutralizing effect Effects 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 6
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 6
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- SBBFSIQOOZQKKP-UHFFFAOYSA-N 4-[[2-[6-fluoro-3-[(4-fluorophenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]ethylamino]methyl]-n-propan-2-ylaniline Chemical compound C1=CC(NC(C)C)=CC=C1CNCCN1C(CC=2C=CC(F)=CC=2)CC2=CC(F)=CC=C2C1 SBBFSIQOOZQKKP-UHFFFAOYSA-N 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000003074 dental pulp Anatomy 0.000 description 42
- 229960001322 trypsin Drugs 0.000 description 33
- 210000004262 dental pulp cavity Anatomy 0.000 description 31
- 210000005258 dental pulp stem cell Anatomy 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 210000004268 dentin Anatomy 0.000 description 17
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000002101 nanobubble Substances 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 13
- 239000002504 physiological saline solution Substances 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 11
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 9
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 9
- 102000004856 Lectins Human genes 0.000 description 9
- 108090001090 Lectins Proteins 0.000 description 9
- 102000012479 Serine Proteases Human genes 0.000 description 9
- 108010022999 Serine Proteases Proteins 0.000 description 9
- 239000002523 lectin Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 8
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 230000014511 neuron projection development Effects 0.000 description 7
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 6
- 102100023688 Eotaxin Human genes 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- -1 tetrahydroisoquinoline compound Chemical class 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 108010045569 atelocollagen Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 239000003178 glass ionomer cement Substances 0.000 description 4
- 230000002439 hemostatic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004416 odontoblast Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 3
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000011316 allogeneic transplantation Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 102100034134 Activin receptor type-1B Human genes 0.000 description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000219774 Griffonia Species 0.000 description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- WDUANCPTTZQWSY-UHFFFAOYSA-N n-[3-[[2-[6-fluoro-3-[(4-fluorophenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]ethylamino]methyl]phenyl]methanesulfonamide Chemical group CS(=O)(=O)NC1=CC=CC(CNCCN2C(CC3=CC(F)=CC=C3C2)CC=2C=CC(F)=CC=2)=C1 WDUANCPTTZQWSY-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DACZKWNOZUFNRP-UHFFFAOYSA-N 2-[6-fluoro-3-[(4-fluorophenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-4-ylmethyl)ethanamine Chemical compound C1=CC(F)=CC=C1CC1N(CCNCC=2C=CN=CC=2)CC2=CC=C(F)C=C2C1 DACZKWNOZUFNRP-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- LGLSWIYCJZCHHJ-UHFFFAOYSA-N 4-[[2-[6-fluoro-3-[(4-fluorophenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]ethylamino]methyl]-n-(2-methoxyethyl)aniline Chemical compound C1=CC(NCCOC)=CC=C1CNCCN1C(CC=2C=CC(F)=CC=2)CC2=CC(F)=CC=C2C1 LGLSWIYCJZCHHJ-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 235000015256 Chionanthus virginicus Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 101710197072 Lectin 1 Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- OMTYJLWYMJDIKD-UHFFFAOYSA-N N-[3-[[2-[6-fluoro-3-[(4-fluorophenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]ethylamino]methyl]phenyl]methanesulfonamide 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CS(=O)(=O)NC1=CC=CC(CNCCN2C(CC3=CC(F)=CC=C3C2)CC=2C=CC(F)=CC=2)=C1 OMTYJLWYMJDIKD-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710174704 Subtilisin-like serine protease Proteins 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108090000200 cucumisin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000004480 periapical periodontitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010031354 thermitase Proteins 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000004746 tooth root Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/54—Filling; Sealing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(式中、
R1、R2、R3、R4は、それぞれ独立して、-H、-ハロゲン、置換もしくは非置換のC1-6アルキル、-OH、-O-C1-6アルキル、-SH、-S-C1-6アルキル、-COOH、-CO-C1-6アルキル、-CO-O-C1-6アルキル、-CO-NH-C1-6アルキル、-NO2、-NH2、-NH-C1-6アルキル、-N(C1-6アルキル)2、または-NH-CO-C1-6アルキルであり、
R5は、置換もしくは非置換のC1-6アルキル、置換もしくは非置換のC3-10シクロアルキル、置換もしくは非置換のC6-14アリール、-C1-6アルキレン-置換もしくは非置換のC3-10シクロアルキル、または-C1-6アルキレン-置換もしくは非置換のC6-14アリールを示し、
R6は、-H、置換もしくは非置換の-C1-6アルキル、または-Y’-A’を示し、
Xは、C1-6アルキレンを示し、
YおよびY’は、それぞれ独立して、単結合またはC1-6アルキレンを示し、
AおよびA’は、それぞれ独立して、置換もしくは非置換のC6-14アリールまたは置換もしくは非置換の3~15員のヘテロ環基を示し、
nは、0または1を示す。)
で示されるテトラヒドロイソキノリン化合物もしくはその薬学的に許容される塩またはそれらの溶媒和物を含んでなる、非細胞性根管充填材を提供するものである。
(式中、
R1、R2、R3、R4は、それぞれ独立して、-H、-ハロゲン、置換もしくは非置換のC1-6アルキル、-OH、-O-C1-6アルキル、-SH、-S-C1-6アルキル、-COOH、-CO-C1-6アルキル、-CO-O-C1-6アルキル、-CO-NH-C1-6アルキル、-NO2、-NH2、-NH-C1-6アルキル、-N(C1-6アルキル)2、または-NH-CO-C1-6アルキルであり、
R5は、置換もしくは非置換のC1-6アルキル、置換もしくは非置換のC3-10シクロアルキル、置換もしくは非置換のC6-14アリール、-C1-6アルキレン-置換もしくは非置換のC3-10シクロアルキル、または-C1-6アルキレン-置換もしくは非置換のC6-14アリールを示し、
R6は、-H、置換もしくは非置換の-C1-6アルキル、または-Y’-A’を示し、
Xは、C1-6アルキレンを示し、
YおよびY’は、それぞれ独立して、単結合またはC1-6アルキレンを示し、
AおよびA’は、それぞれ独立して、置換もしくは非置換のC6-14アリールまたは置換もしくは非置換の3~15員のヘテロ環基を示し、
nは、0または1を示す。)
で示されるテトラヒドロイソキノリン化合物もしくはその薬学的に許容される塩またはそれらの溶媒和物(以降、本明細書では、「化合物群A」と記載する)を含んでなる、非細胞性根管充填材である。
(若齢イヌの抜髄後歯髄再生)
全身麻酔を施した後、若齢(12か月齢)のイヌ上下顎左右前歯部に抜髄処置を行い、根尖部まで#55で拡大後、5%次亜塩素酸ナトリウム溶液と3%過酸化水素水で交互洗浄し、生理食塩水で洗浄し、乾燥後、レジンにて完全に仮封した。抜髄処置の3~12日後に仮封をはずし、再度、交互洗浄、生理食塩水で洗浄した。その後、根管内を3%EDTA(スメアクリーン、日本歯科薬品)で満たし、2分間作用させ、さらに生理食塩水で洗浄し、乾燥させた。その後、根管内にトリプシン製剤(フランセチンTパウダー(持田製薬)(10 mgあたり結晶トリプシン 2,500 USP))5 mg/ml(0.5%、ナノバブル水(Foamest 8(ナック販売)により調製;庵原耕一郎、中島美砂子「難治性根尖性歯周炎における薬剤含有ナノバブル水による根管内除菌効果の検討」、日本歯科保存学雑誌、第63巻第1号p.73~82参照)に溶解)を10分間適用することにより前処理を行い、その後、生理食塩水で洗浄した。次いで、細胞外基質であるコラーゲン(コーケンアテロコラーゲンインプラント、高研)20μlに、再生促進化合物としてCCR3アンタゴニスト(1.25μgの化合物B、または0.83μgのSB328437(Tocris Bioscience))、遊走因子として150ngのG-CSF(ノイトロジン、中外製薬)を添加した非細胞性根管充填材を調製し、根管に充填した。その後、その上に止血用ゼラチンスポンジ(スポンゼル、アステラス製薬)を置き、グラスアイオノマーセメントおよび光重合レジンにて窩洞を完全封鎖した。移植28日後に抜歯し、通法に従って縦断面の5μmパラフィン切片を作製し、H-E染色後、形態観察を行った。歯髄再生量は、1サンプルにつき4枚の切片について、歯髄腔の面積に対する再生歯髄の面積の比率を測定し、4サンプルの平均値を算出して評価した。血管新生は、28日標本を、Fluorescein labeled Griffonia (Bandeiraea) Simplicifolia Lectin I (GSL I, BSL I)およびFluorescein labeled Galanthus Nivalis (Snowdrop) Lectin (GNL)(ベクターラボラトリーズ)(20μg/ml)により15分間染色し、比較検討を行った。神経突起伸長は、28日標本にを、抗PGP9.5抗体(UltraClone、1:10,000)により免疫染色し、比較検討を行った。
(化合物Bの有無による若齢イヌの抜髄後歯髄再生の比較)
全身麻酔を施した後、若齢(11か月齢)のイヌ上下顎左右前歯部に抜髄処置を行い、根尖部まで#55で拡大後、5%次亜塩素酸ナトリウム溶液と3%過酸化水素水で交互洗浄し、生理食塩水で洗浄し、ペーパーポイントで根管内を完全乾燥、止血した後、セメントとレジンにて完全に仮封した。抜髄処置8日後、仮封をはずし、再度、交互洗浄、生理食塩水で洗浄した。その後、根管内を3%EDTA(スメアクリーン、日本歯科薬品)で満たし、2分間作用させ、さらに生理食塩水で洗浄し、乾燥させた。その後、根管内にトリプシン製剤(フランセチンTパウダー(持田製薬)(10 mgあたり結晶トリプシン 2,500 USP))5 mg/ml(0.5%、ナノバブル水(Foamest 8(ナック販売)により調製、実施例1に同じ)に溶解)を10分間適用することにより前処理を行い、その後、生理食塩水で洗浄した。次いで、細胞外基質であるコラーゲン(コーケンアテロコラーゲンインプラント、高研)20μlに、再生促進化合物として1.25μgの化合物B、遊走因子として150ngのG-CSF(ノイトロジン、中外製薬)を添加した非細胞性根管充填材を調製し、根管に充填した。一方、化合物Bを含まない以外は同様の組成の非細胞性根管充填材を、同様の手順により根管に充填したものを対照とした。その後、その上に止血用ゼラチンスポンジ(スポンゼル、アステラス製薬)を置き、グラスアイオノマーセメントおよび光重合レジンにて窩洞を完全封鎖した。移植28日後に抜歯し、実施例1と同様にして、通法に従って縦断面の5μmパラフィン切片を作製し、H-E染色後、形態観察を行った。また、実施例1と同様にして、血管新生はBS-1 lectin染色により、神経突起伸長はPGP9.5の免疫染色により確認した。
(トリプシン前処理の有無による若齢イヌの抜髄後歯髄再生の比較)
全身麻酔を施した後、若齢(11か月齢)のイヌ下顎左右前歯部に抜髄処置を行い、根尖部まで#50で拡大後、5%次亜塩素酸ナトリウム溶液と3%過酸化水素水で交互洗浄し、生理食塩水で洗浄し、ペーパーポイントで根管内を完全乾燥、止血した後、セメントとレジンにて完全に仮封した。抜髄処置後、仮封をはずし、再度、交互洗浄、生理食塩水で洗浄した。その後、根管内を3%EDTA(スメアクリーン、日本歯科薬品)で満たし、2分間作用させ、さらに生理食塩水で洗浄し、乾燥させた。その後、左側の根管内にトリプシン製剤(フランセチンTパウダー(持田製薬)(10 mgあたり結晶トリプシン 2,500 USP))5 mg/ml(0.5%、ナノバブル水(Foamest 8(ナック販売)により調製、実施例1に同じ)に溶解)を10分間適用することにより前処理を行い、その後、生理食塩水で洗浄した。一方、右側の根管については、上記前処理を行わなかった(対照)。次いで、細胞外基質であるコラーゲン(コーケンアテロコラーゲンインプラント、高研)20μlに、再生促進化合物として1.25μgの化合物B、遊走因子として150ngのG-CSF(ノイトロジン、中外製薬)を添加した非細胞性根管充填材を調製し、左右の根管に充填した。その後、その上に止血用ゼラチンスポンジ(スポンゼル、アステラス製薬)を置き、グラスアイオノマーセメントおよび光重合レジンにて窩洞を完全封鎖した。移植28日後に抜歯し、実施例1と同様にして、通法に従って縦断面の5μmパラフィン切片を作製し、H-E染色後、形態観察を行った。また、実施例1と同様にして、血管新生はBS-1 lectin染色により、神経突起伸長はPGP9.5の免疫染色により確認した。
(化合物Cの有無による若齢イヌの抜髄後歯髄再生の比較)
全身麻酔を施した後、若齢(11か月齢)のイヌ上下顎左右前歯部に抜髄処置を行い、根尖部まで#60で拡大後、5%次亜塩素酸ナトリウム溶液と3%過酸化水素水で交互洗浄し、生理食塩水で洗浄し、ペーパーポイントで根管内を完全乾燥、止血した後、セメントとレジンにて完全に仮封した。抜髄処置後、仮封をはずし、再度、交互洗浄、生理食塩水で洗浄した。その後、根管内を3%EDTA(スメアクリーン、日本歯科薬品)で満たし、2分間作用させ、さらに生理食塩水で洗浄し、乾燥させた。その後、根管内にトリプシン製剤(フランセチンTパウダー(持田製薬)(10 mgあたり結晶トリプシン 2,500 USP))0.5 mg/ml(0.05%、ナノバブル水(Foamest 8(ナック販売)により調製、実施例1に同じ)に溶解)を10分間適用することにより前処理を行い、その後、生理食塩水で洗浄した。次いで、細胞外基質であるコラーゲン(コーケンアテロコラーゲンインプラント、高研)20μlに、再生促進化合物として1.2μgの化合物C、遊走因子として150ngのG-CSF(ノイトロジン、中外製薬)を添加した非細胞性根管充填材を調製し、根管に充填した。一方、化合物Cを含まない以外は同様の組成の非細胞性根管充填材を、同様の手順により根管に充填したものを対照とした。その後、その上に止血用ゼラチンスポンジ(スポンゼル、アステラス製薬)を置き、グラスアイオノマーセメントおよび光重合レジンにて窩洞を完全封鎖した。移植28日後に抜歯し、実施例1と同様にして、通法に従って縦断面の5μmパラフィン切片を作製し、H-E染色後、形態観察を行った。象牙質の面積は、3サンプルにつき1枚の切片について、歯の面積に対する象牙質の面積の比率を測定し、3サンプルの平均値を算出して評価した。象牙質細胞の密度は、3サンプルにつき1枚の切片について、根管側壁から1mmの範囲に含まれる象牙質細胞数を計測することにより算出した。
Claims (10)
- (+)-4-[[2-[6-フルオロ-3-(4-フルオロベンジル)-3,4-ジヒドロイソキノリン-2(1H)-イル]エチルアミノ]メチル]-N-イソプロピルアニリン・1フマル酸塩または(+)-N-[3-(メタンスルホニルアミノ)ベンジル]-2-[6-フルオロ-3-(4-フルオロベンジル)-3,4-ジヒドロイソキノリン-2(1H)-イル]エタンアミン・1クエン酸塩を含んでなる、非細胞性根管充填材。
- 細胞外基質をさらに含む、請求項1に記載の非細胞性根管充填材。
- G-CSF、bFGFおよびSDF-1からなる群から選択される少なくとも一つの遊走因子をさらに含む、請求項1~3のいずれか1項に記載の非細胞性根管充填材。
- 若齢個体の歯組織の再生のために使用される、請求項1~4のいずれか1項に記載の非細胞性根管充填材。
- トリプシンを含む前処理剤と、
(+)-4-[[2-[6-フルオロ-3-(4-フルオロベンジル)-3,4-ジヒドロイソキノリン-2(1H)-イル]エチルアミノ]メチル]-N-イソプロピルアニリン・1フマル酸塩または(+)-N-[3-(メタンスルホニルアミノ)ベンジル]-2-[6-フルオロ-3-(4-フルオロベンジル)-3,4-ジヒドロイソキノリン-2(1H)-イル]エタンアミン・1クエン酸塩と
を含んでなる、歯組織再生促進キット。 - 前記非細胞性根管充填材が細胞外基質をさらに含む、請求項6に記載の歯組織再生促進キット。
- 前記非細胞性根管充填材が、G-CSF、bFGFおよびSDF-1からなる群から選択される少なくとも一つの遊走因子をさらに含む、請求項6~8のいずれか1項に記載の歯組織再生促進キット。
- 中高齢個体の歯組織の再生のために使用される、請求項6~9のいずれか1項に記載の歯組織再生促進キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019062054 | 2019-03-28 | ||
JP2019062054 | 2019-03-28 | ||
PCT/JP2020/014166 WO2020196867A1 (ja) | 2019-03-28 | 2020-03-27 | 非細胞性根管充填材および非細胞性歯組織再生促進キット |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2020196867A1 JPWO2020196867A1 (ja) | 2020-10-01 |
JP7212144B2 true JP7212144B2 (ja) | 2023-01-24 |
Family
ID=72609503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021509662A Active JP7212144B2 (ja) | 2019-03-28 | 2020-03-27 | 非細胞性根管充填材および非細胞性歯組織再生促進キット |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220362109A1 (ja) |
EP (1) | EP3949991A4 (ja) |
JP (1) | JP7212144B2 (ja) |
KR (1) | KR20210144710A (ja) |
CN (1) | CN113784726B (ja) |
AU (1) | AU2020248566A1 (ja) |
BR (1) | BR112021018803A2 (ja) |
CA (1) | CA3133470A1 (ja) |
SG (1) | SG11202109789XA (ja) |
WO (1) | WO2020196867A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11890154B2 (en) * | 2021-06-30 | 2024-02-06 | Khalid AL HEZAIMI | Pulp capping methods |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008123582A1 (ja) | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
JP2009173571A (ja) | 2008-01-23 | 2009-08-06 | Kowa Co | (+)−4−[[2−[6−フルオロ−3−(4−フルオロベンジル)−3,4−ジヒドロイソキノリン−2(1h)−イル]エチルアミノ]メチル]−n−イソプロピルアニリン・1フマル酸塩及びその結晶多形体 |
JP2009191048A (ja) | 2008-02-18 | 2009-08-27 | Kowa Co | (+)−n−[3−(メタンスルホニルアミノ)ベンジル]−2−[6−フルオロ−3−(4−フルオロベンジル)−3,4−ジヒドロイソキノリン−2(1h)−イル]エタンアミン・1クエン酸塩。 |
WO2016084780A1 (ja) | 2014-11-24 | 2016-06-02 | 有限会社中島工業 | 患部浸透亢進性薬剤組成物 |
WO2017170996A1 (ja) | 2016-03-31 | 2017-10-05 | 国立研究開発法人国立長寿医療研究センター | 歯科用前処理材及び歯組織再生キット |
JP2019063191A (ja) | 2017-09-29 | 2019-04-25 | 国立研究開発法人国立長寿医療研究センター | 非細胞性根管充填材及び非細胞性歯組織再生促進キット |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5166862A (ja) | 1974-12-06 | 1976-06-09 | Boeicho Gijutsu Kenkyu Honbuch | Hoisokuteihoshiki |
DE2518111C3 (de) | 1975-03-21 | 1981-01-22 | H. Krantz Gmbh & Co, 5100 Aachen | Verfahren zur Naßbehandlung von Textilgut |
JPS51144794A (en) | 1975-06-09 | 1976-12-13 | Kanegafuchi Chem Ind Co Ltd | Process for preparing yeast protein |
JPS6031658B2 (ja) | 1976-11-15 | 1985-07-23 | 古河電気工業株式会社 | 熱可塑性樹脂発泡網状体の製造方法 |
US7122533B2 (en) * | 1999-11-29 | 2006-10-17 | The United States Of America As Represented By The Department Of Health And Human Services | Cosalane compounds and methods for their use |
JP5621105B2 (ja) | 2008-03-12 | 2014-11-05 | 公益財団法人ヒューマンサイエンス振興財団 | 根管充填材 |
WO2011030552A1 (ja) | 2009-09-11 | 2011-03-17 | 独立行政法人国立長寿医療研究センター | 非抜歯根管充填材及び非抜歯による歯組織再生方法 |
JP5939559B2 (ja) | 2011-02-28 | 2016-06-22 | 国立研究開発法人国立長寿医療研究センター | 間葉系幹細胞を含んでなる根管充填材、及びこれを用いた歯組織再生方法 |
KR101626456B1 (ko) * | 2013-09-13 | 2016-06-01 | 서울대학교산학협력단 | 프롤릴 히드록실라아제 저해제 또는 히스톤 탈아세틸라아제 저해제, 및 항생제를 포함하는 치수 재생 치료 또는 치근첨 형성 유도 치료용 약학적 조성물, 및 이를 포함하는 합성고분자 나노섬유메시 |
EP3568141B1 (en) * | 2017-01-16 | 2020-12-16 | Cells for Cells S.A. | Composition comprising a substantially pure population of multipotent stromal cells encapsulated in platelet-poor plasma (ppp) |
-
2020
- 2020-03-27 EP EP20776667.6A patent/EP3949991A4/en active Pending
- 2020-03-27 CN CN202080024967.7A patent/CN113784726B/zh active Active
- 2020-03-27 CA CA3133470A patent/CA3133470A1/en active Pending
- 2020-03-27 SG SG11202109789X patent/SG11202109789XA/en unknown
- 2020-03-27 BR BR112021018803A patent/BR112021018803A2/pt unknown
- 2020-03-27 AU AU2020248566A patent/AU2020248566A1/en active Pending
- 2020-03-27 KR KR1020217030121A patent/KR20210144710A/ko active Search and Examination
- 2020-03-27 JP JP2021509662A patent/JP7212144B2/ja active Active
- 2020-03-27 WO PCT/JP2020/014166 patent/WO2020196867A1/ja unknown
- 2020-03-27 US US17/441,611 patent/US20220362109A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008123582A1 (ja) | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
JP2009173571A (ja) | 2008-01-23 | 2009-08-06 | Kowa Co | (+)−4−[[2−[6−フルオロ−3−(4−フルオロベンジル)−3,4−ジヒドロイソキノリン−2(1h)−イル]エチルアミノ]メチル]−n−イソプロピルアニリン・1フマル酸塩及びその結晶多形体 |
JP2009191048A (ja) | 2008-02-18 | 2009-08-27 | Kowa Co | (+)−n−[3−(メタンスルホニルアミノ)ベンジル]−2−[6−フルオロ−3−(4−フルオロベンジル)−3,4−ジヒドロイソキノリン−2(1h)−イル]エタンアミン・1クエン酸塩。 |
WO2016084780A1 (ja) | 2014-11-24 | 2016-06-02 | 有限会社中島工業 | 患部浸透亢進性薬剤組成物 |
WO2017170996A1 (ja) | 2016-03-31 | 2017-10-05 | 国立研究開発法人国立長寿医療研究センター | 歯科用前処理材及び歯組織再生キット |
JP2019063191A (ja) | 2017-09-29 | 2019-04-25 | 国立研究開発法人国立長寿医療研究センター | 非細胞性根管充填材及び非細胞性歯組織再生促進キット |
Also Published As
Publication number | Publication date |
---|---|
EP3949991A1 (en) | 2022-02-09 |
BR112021018803A2 (pt) | 2021-11-23 |
SG11202109789XA (en) | 2021-10-28 |
CA3133470A1 (en) | 2020-10-01 |
US20220362109A1 (en) | 2022-11-17 |
EP3949991A4 (en) | 2023-05-24 |
WO2020196867A1 (ja) | 2020-10-01 |
KR20210144710A (ko) | 2021-11-30 |
AU2020248566A1 (en) | 2021-10-07 |
CN113784726A (zh) | 2021-12-10 |
CN113784726B (zh) | 2023-07-28 |
JPWO2020196867A1 (ja) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Platelet-rich fibrin is a Bioscaffold and reservoir of growth factors for tissue regeneration | |
EP2476442B1 (en) | Root canal filler for non-extracted tooth and non-extraction method for regenerating dental tissue | |
JP5572291B2 (ja) | 歯髄及び/又は象牙質形成促進のための薬剤及びその利用 | |
JP5313209B2 (ja) | 歯周病と歯髄疾患の治療剤と治療方法 | |
JP7112538B2 (ja) | 根管充填材 | |
JP2022116298A (ja) | 非細胞性根管充填材及び非細胞性歯組織再生促進キット | |
US20090068154A1 (en) | Cell Composition for Transplant | |
JP7212144B2 (ja) | 非細胞性根管充填材および非細胞性歯組織再生促進キット | |
Albonni et al. | Clinical effectiveness of a topical subgingival application of injectable platelet-rich fibrin as adjunctive therapy to scaling and root planing: a double-blind, split-mouth, randomized, prospective, comparative controlled trial | |
RU2812019C2 (ru) | Неклеточный наполнитель корневого канала и неклеточный набор, стимулирующий регенерацию тканей зуба | |
Rubine | Evaluation of Effectiveness of Concentrated Growth Factor with Bovine Porous Bone Mineral as Compared to Bovine Porous Bone Mineral Alone in the Treatment of Intra Bony Defects: A Split Mouth Study | |
Elkhatat | Role of platelet-rich fibrin in periodontal regeneration | |
Keyhan et al. | Regenerative Approaches in Oral and Maxillofacial Surgery | |
Indurkar et al. | Assessment of quantitative relationship between blood and PRF for periodontal surgeries | |
Creber | Engineering Periodontal Tissue Regeneration with the Use of a Novel Periostin Electrospun Scaffold | |
Sethi | Comparative evaluation of Bio-resorbable collagen membrane (Bio-gide perio) with and without autologous platelet-rich plasma (PRP) in the treatment of periodontal intrabony defects-a clinical study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220527 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221223 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7212144 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |